📊 GPLB Key Takeaways
Is GPLB a Good Investment? Thesis Analysis
Green Planet Bio Engineering exhibits severe financial distress with negative stockholders' equity of -$501K, zero reportable assets, and zero cash reserves, indicating technical insolvency. The company generates no revenue, reports continuous operating losses (-$35.8K), and negative free cash flow, with liabilities of $283.6K covering assets that are essentially non-existent, making the company unable to meet current financial obligations.
Green Planet Bio Engineering shows no operating revenue, zero assets, and negative shareholders’ equity. Persistent operating and cash losses with a 0.00x current ratio indicate severe going‑concern and dilution risk. Until financing is secured and operations resume with visible margins, fundamentals are untenable.
Why Buy GPLB? Key Strengths
- Financial data transparency available via SEC filings
- SIC classification indicates biotech/biological products sector
- Company maintains OTC exchange listing
- No long-term debt disclosed
- Low absolute operating cash burn (~$36K)
- Liabilities are modest in absolute terms (~$284K)
GPLB Investment Risks to Consider
- Negative stockholders equity of -$501K indicates technical insolvency
- Total assets reported at $0.00 with $283.6K in liabilities
- Zero cash and equivalents with $0.00 current ratio - unable to pay current liabilities
- No reportable revenue despite biotech sector focus
- Negative operating and free cash flow (-$36.5K) with no path to profitability
- Zero insider Form 4 filings in 90 days indicates no management confidence
- Characteristics suggest potential shell company or defunct operations
- Zero cash and assets with negative equity (insolvency risk)
- No revenue and continued losses; unclear path to profitability
- High likelihood of dilution or unfavorable financing to remain a going concern
Key Metrics to Watch
- Balance sheet restructuring or debt forgiveness announcements
- Achievement of any positive revenue or gross revenue figures
- Capital infusion or financing events to restore positive equity
- Changes in asset base and cash position in next filing
- Cash & equivalents
- Revenue and initial gross margin
GPLB Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
GPLB Profitability Ratios
GPLB vs Healthcare Sector
How Green Planet Bio Engineering Co. Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GPLB Overvalued or Undervalued?
Based on fundamental analysis, Green Planet Bio Engineering Co. Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GPLB Balance Sheet & Liquidity
GPLB 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Green Planet Bio Engineering Co. Ltd.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
GPLB Growth Metrics (YoY)
GPLB Capital Allocation
GPLB SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Green Planet Bio Engineering Co. Ltd. (CIK: 0001392449)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GPLB
What is the AI rating for GPLB?
Green Planet Bio Engineering Co. Ltd. (GPLB) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GPLB's key strengths?
Claude: Financial data transparency available via SEC filings. SIC classification indicates biotech/biological products sector. ChatGPT: No long-term debt disclosed. Low absolute operating cash burn (~$36K).
What are the risks of investing in GPLB?
Claude: Negative stockholders equity of -$501K indicates technical insolvency. Total assets reported at $0.00 with $283.6K in liabilities. ChatGPT: Zero cash and assets with negative equity (insolvency risk). No revenue and continued losses; unclear path to profitability.
What is GPLB's revenue and growth?
Green Planet Bio Engineering Co. Ltd. reported revenue of N/A.
Does GPLB pay dividends?
Green Planet Bio Engineering Co. Ltd. does not currently pay dividends.
Where can I find GPLB SEC filings?
Official SEC filings for Green Planet Bio Engineering Co. Ltd. (CIK: 0001392449) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GPLB's EPS?
Green Planet Bio Engineering Co. Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GPLB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Green Planet Bio Engineering Co. Ltd. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GPLB stock overvalued or undervalued?
Valuation metrics for GPLB: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GPLB stock in 2026?
Our dual AI analysis gives Green Planet Bio Engineering Co. Ltd. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GPLB's free cash flow?
Green Planet Bio Engineering Co. Ltd.'s operating cash flow is $-36.5K, with capital expenditures of N/A.
How does GPLB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 2).